The modulation of ACE2 cell-surface expression differed from one cell population to another as illustrated by the significantly higher number of CD3+ T cells expressing ACE2 in the COVID-19 patients groups, while there was an absence of modulation in the CD20+ B cells and CD16+/HLA-DR+ monocytic/dendritic cells expressing ACE2 compared to cell populations from healthy volunteers (Figure S1;Supplementary Data). The gene discussed is ACE2; the disease is COVID-19.